View Older Stories View More Recent Stories
-
Pfizer (PFE) To Spend Up To $15 Billion This Year To Boost Pipeline - Bloomberg
-
Pfizer (PFE) Tops Q1 EPS by 24c; offers guidance
-
Pfizer earnings preview Q1: soft print expected; weight loss pill, tariff impact in focus
-
Pfizer (PFE) call put ratio 2.4 calls to 1 put into quarter results
-
Pfizer (PFE) May 2 weekly 23 straddle into quarter results
-
Guardant Health (GH) Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
-
Pfizer (PFE) Declares $0.43 Quarterly Dividend; 7.7% Yield
-
Cantor Fitzgerald Starts Pfizer (PFE) at Neutral
-
Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE)
-
Morgan Stanley Reiterates Equalweight Rating on Pfizer (PFE)
-
Leerink Partners Reiterates Market Perform Rating on Pfizer (PFE)
-
Trump: We'll Do Pharma Tariffs
-
Pfizer (PFE) Discontinues danuglipron
-
Pharma stocks slide after Trump signals tariffs on sector
-
Pfizer (PFE) PT Lowered to $24 at UBS
-
Goldman Sachs Downgrades Pfizer (PFE) to Neutral
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
Pfizer (PFE) Announces EU Approval of ABRYSVO
-
Truist: 'Expect Some Pressure On Dr. Marks' Resignation'
-
Berenberg Reiterates Hold Rating on Pfizer (PFE)
-
Citi on Pfizer (PFE)
-
U.S. probing GSK's tip about timing of Pfizer (PFE) vaccine - WSJ
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Active options: PFE COIN BABA INTC F HOOD GOOGL MU MSFT MARA WMT
-
Will Pfizer step into the obesity ring? Wolfe Research answers
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Arvinas Inc. (ARVN) and Pfizer (PFE) Announce Positive Topline Results from Phase 3 VERITAC-2 Trial
-
CDC Plans Large Study Into Potential Connections Between Vaccines and Autism - Reuters
-
Pfizer (PFE) Appoints James List as Chief Internal Medicine Officer
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
Pfizer (PFE) PT Lowered to $30 at Bernstein; 'We Need to See More'
-
Pfizer (PFE) Announces New Chief Medical Officer
-
Summit Therapeutics (SMMT) Announces Clinical Trial Collaboration with Pfizer (PFE) to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
-
Clorox (CLX) gains 2.7% on new virus concerns
-
Moderna (MRNA) Strength tied to Speculation About New Coronavirus
-
Pfizer (PFE) Will End Global Development and Commercialization of Beqvez - Nikkei
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board of Directors for Breach of Fiduciary Duties (PFE)
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
Pfizer (PFE) stock: What could right the ship according to Wolfe
-
RFK, Jr. said confirmed
-
Pfizer (PFE) Reports TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
House Speaker Johnson Says He Believes The White House Is Considering Exemptions To Reciprocal Tariffs Including Autos And Pharmaceuticals - Reuters
-
Pfizer (PFE): U.S. FDA Approves Pfizer’s ADCETRIS Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-
Pfizer (PFE) PT Raised to $34 at Jefferies
-
Pfizer (PFE) and Astellas PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of la/mUC
-
Pfizer (PFE) PT Lowered to $32 at Goldman Sachs
